Cargando…

Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age

Trabectedin has mostly been studied in metastatic leiomyosarcoma and liposarcomas. Only limited data are available in other sarcoma subtypes, heavily pretreated and elderly patients. We retrospectively analyzed 101 consecutive sarcoma patients treated with trabectedin at our center. We recorded prog...

Descripción completa

Detalles Bibliográficos
Autores principales: HOICZYK, MATHIAS, GRABELLUS, FLORIAN, PODLESKA, LARS, AHRENS, MARIT, SCHWINDENHAMMER, BENJAMIN, TAEGER, GEORG, PÖTTGEN, CHRISTOPH, SCHULER, MARTIN, BAUER, SEBASTIAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742158/
https://www.ncbi.nlm.nih.gov/pubmed/23652821
http://dx.doi.org/10.3892/ijo.2013.1928
_version_ 1782280322581266432
author HOICZYK, MATHIAS
GRABELLUS, FLORIAN
PODLESKA, LARS
AHRENS, MARIT
SCHWINDENHAMMER, BENJAMIN
TAEGER, GEORG
PÖTTGEN, CHRISTOPH
SCHULER, MARTIN
BAUER, SEBASTIAN
author_facet HOICZYK, MATHIAS
GRABELLUS, FLORIAN
PODLESKA, LARS
AHRENS, MARIT
SCHWINDENHAMMER, BENJAMIN
TAEGER, GEORG
PÖTTGEN, CHRISTOPH
SCHULER, MARTIN
BAUER, SEBASTIAN
author_sort HOICZYK, MATHIAS
collection PubMed
description Trabectedin has mostly been studied in metastatic leiomyosarcoma and liposarcomas. Only limited data are available in other sarcoma subtypes, heavily pretreated and elderly patients. We retrospectively analyzed 101 consecutive sarcoma patients treated with trabectedin at our center. We recorded progression-free survival (PFS), clinical benefit rate (CBR, defined as complete or partial response or stable disease for at least 6 weeks) and toxicity. Covariates were sarcoma subtype, age and pretreatment. On average, trabectedin was administered for 2nd relapse/progression (range 1st to 12th line). A median of 2 cycles and a dose of 1.5 mg/m(2) (range 1–21 cycles; 1.3–1.5 mg/m(2)) was administered. The median PFS under treatment with trabectedin was 2.1 months in the overall population. Different clinical outcomes were observed with respect to sarcoma subtypes: in patients with L-sarcoma [defined as leiosarcoma and liposarcoma (n=25)] the CBR was 55%. Notably, long lasting remissions were even observed in 7th-line treatment. In contrast, the majority of patients with non-L-sarcomas quickly progressed (median PFS 1.6 months). Nevertheless, a CBR of 34% was achieved, including long-lasting disease stabilization in subtypes such as rhabdomyosarcoma. Patients treated with trabectedin at 1st or 2nd line (n=16) achieved an improved PFS (median 5.7 months, range) and a CBR of 59%. No differences in terms of toxicity or efficacy were observed between patients older than 65 years (n=23) and younger patients (n=78). In this non-trial setting, port-associated complications were more frequent (14%) with trabectedin compared to other continuous infusion protocols administered at our outpatient therapy center. The majority of patients with relapsing L-sarcomas and a substantial fraction of patients with non-L-sarcomas derive a clinically meaningful benefit from trabectedin. Outpatient treatment is well tolerated also in elderly and heavily pretreated patients. Port-associated complications were observed at an unusually high rate. This suggests a drug-specific local toxicity that merits further investigation.
format Online
Article
Text
id pubmed-3742158
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-37421582013-08-14 Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age HOICZYK, MATHIAS GRABELLUS, FLORIAN PODLESKA, LARS AHRENS, MARIT SCHWINDENHAMMER, BENJAMIN TAEGER, GEORG PÖTTGEN, CHRISTOPH SCHULER, MARTIN BAUER, SEBASTIAN Int J Oncol Articles Trabectedin has mostly been studied in metastatic leiomyosarcoma and liposarcomas. Only limited data are available in other sarcoma subtypes, heavily pretreated and elderly patients. We retrospectively analyzed 101 consecutive sarcoma patients treated with trabectedin at our center. We recorded progression-free survival (PFS), clinical benefit rate (CBR, defined as complete or partial response or stable disease for at least 6 weeks) and toxicity. Covariates were sarcoma subtype, age and pretreatment. On average, trabectedin was administered for 2nd relapse/progression (range 1st to 12th line). A median of 2 cycles and a dose of 1.5 mg/m(2) (range 1–21 cycles; 1.3–1.5 mg/m(2)) was administered. The median PFS under treatment with trabectedin was 2.1 months in the overall population. Different clinical outcomes were observed with respect to sarcoma subtypes: in patients with L-sarcoma [defined as leiosarcoma and liposarcoma (n=25)] the CBR was 55%. Notably, long lasting remissions were even observed in 7th-line treatment. In contrast, the majority of patients with non-L-sarcomas quickly progressed (median PFS 1.6 months). Nevertheless, a CBR of 34% was achieved, including long-lasting disease stabilization in subtypes such as rhabdomyosarcoma. Patients treated with trabectedin at 1st or 2nd line (n=16) achieved an improved PFS (median 5.7 months, range) and a CBR of 59%. No differences in terms of toxicity or efficacy were observed between patients older than 65 years (n=23) and younger patients (n=78). In this non-trial setting, port-associated complications were more frequent (14%) with trabectedin compared to other continuous infusion protocols administered at our outpatient therapy center. The majority of patients with relapsing L-sarcomas and a substantial fraction of patients with non-L-sarcomas derive a clinically meaningful benefit from trabectedin. Outpatient treatment is well tolerated also in elderly and heavily pretreated patients. Port-associated complications were observed at an unusually high rate. This suggests a drug-specific local toxicity that merits further investigation. D.A. Spandidos 2013-05-02 /pmc/articles/PMC3742158/ /pubmed/23652821 http://dx.doi.org/10.3892/ijo.2013.1928 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
HOICZYK, MATHIAS
GRABELLUS, FLORIAN
PODLESKA, LARS
AHRENS, MARIT
SCHWINDENHAMMER, BENJAMIN
TAEGER, GEORG
PÖTTGEN, CHRISTOPH
SCHULER, MARTIN
BAUER, SEBASTIAN
Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age
title Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age
title_full Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age
title_fullStr Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age
title_full_unstemmed Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age
title_short Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age
title_sort trabectedin in metastatic soft tissue sarcomas: role of pretreatment and age
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742158/
https://www.ncbi.nlm.nih.gov/pubmed/23652821
http://dx.doi.org/10.3892/ijo.2013.1928
work_keys_str_mv AT hoiczykmathias trabectedininmetastaticsofttissuesarcomasroleofpretreatmentandage
AT grabellusflorian trabectedininmetastaticsofttissuesarcomasroleofpretreatmentandage
AT podleskalars trabectedininmetastaticsofttissuesarcomasroleofpretreatmentandage
AT ahrensmarit trabectedininmetastaticsofttissuesarcomasroleofpretreatmentandage
AT schwindenhammerbenjamin trabectedininmetastaticsofttissuesarcomasroleofpretreatmentandage
AT taegergeorg trabectedininmetastaticsofttissuesarcomasroleofpretreatmentandage
AT pottgenchristoph trabectedininmetastaticsofttissuesarcomasroleofpretreatmentandage
AT schulermartin trabectedininmetastaticsofttissuesarcomasroleofpretreatmentandage
AT bauersebastian trabectedininmetastaticsofttissuesarcomasroleofpretreatmentandage